Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
M & A

Biodim lets NuPharm access French market

  • News

Executive Summary

NuPharm has completed a deal to buy French firm Laboratoire Biodim from Weinberg Capital Partners’ Pharma Omnium International, for an undisclosed sum. “This strategic acquisition enables NuPharm to enter France and expand its European footprint,” the group observed, “into its fifth country after Germany, Spain, Italy and Poland.” Created in 2016, Nupharm was the result of combining five companies – Spain’s Qualigen, Laboratorios Lesvi and Inke; Germany’s Neuraxpharm, which also operates in Poland; and Italy’s FB Health – with investment group Apax Partners.

Table

View full table

Topics

Tags:
M & A
Latest Headlines

MS Pharma Bags Formycon’s Eylea Biosimilar Rights In MENA

Former Sandoz Exec Kellum Avoids Jail Time Over US Price Fixing

Deals In Bag, Dr Reddy’s Sharpens Top 5 Targeted Home Run

Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds

See All
UsernamePublicRestriction

Register

GB000929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By